Recombinant Technologies, LLC (RTL) was initially established to make available bulk quantities of unique and high quality reagents for research at leading academic institutions. Slowly, the company has transformed itself as a drug development company, focusing its efforts on the identification of novel therapies to improve quality of life of Alzheimer s disease patients. The firm has developed small molecules very effective in binding to beta-amyloid peptide, which is the causative factor in the Alzheimer's disease (AD). Treatment with one of these small molecules has reduced the beta-amyloid peptide deposits in the brain and significantly improved the memory parameters of the AD mice model. Although the mechanism of action of these molecules resembles anti-beta amyloid antibodies, these molecules do not activate immune cells or non-specifically bind to other proteins. Using patented molecules, the firm is planning to conduct the IND-enabling preclinical pharmacokinetic and toxicological studies. Part of these studies will be conducted as proposed in a new SBIR phase 2 grant, subject to approval by NIH.
